Hot Stocks: Brokerages view on Avenue Supermarts, Bajaj Finance, ICICI Bank and Sun Pharma
Brokerage firm HSBC maintained a buy rating on Sun Pharma, Citigroup recommended a buy rating on ICICI Bank, JPMorgan has an overweight rating on Bajaj Finance and CLSA recommended a buy rating on Avenue Supermarts.
Brokerage firm HSBC maintained a buy rating on , Citigroup recommended a buy rating on , JPMorgan has an overweight rating on and CLSA recommended a buy rating on .We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
HSBC on Sun Pharma: Buy| Target Rs 1790
HSBC maintained a buy rating on Sun Pharma but raised the target price to Rs 1790 from Rs 1550 earlier.The company has a healthy outlook for its specialty portfolio. The growth runway should continue for the Ilumya brand on the back of the continued strong market demand for anti-IL drugs.
The filing of Nidlegy with the EU regulator in H1CY24 and FDA approval for 900 deuruxolitinib (alopecia drug) are key catalysts for the stock price in the future.
The global investment bank assumes notable gains from gRevlimid in the March quarter.
Operating leverage delta will be prominent from Q4 onwards. Amidst intense price wars, preference is to manage ROA threshold over chasing growth.
Not actively resorting to bulk deposits reflects its focus/confidence in mobilizing granular retail deposits.
Citigroup expects a 4% QoQ deposits growth translating to 17-18% YoY growth.
The listing could place a hold-co discount of 15% on Bajaj Finance. It would potentially remove a medium-term overhang of a bank conversion by 4900 creating two listed NBFCs.
D-MART opened 16 stores in Q4, three ahead of the forecast. Store additions a key focus point for investors.
Rising inflation in palm oil and crude should allow DMART some room on pricing in FY25.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
The filing of Nidlegy with the EU regulator in H1CY24 and FDA approval for 900 deuruxolitinib (alopecia drug) are key catalysts for the stock price in the future.
The global investment bank assumes notable gains from gRevlimid in the March quarter.
Citigroup on ICICI Bank: Buy| Target Rs 1322
Citigroup maintained a buy rating on ICICI Bank with a target price of Rs 1322. The global investment bank has enhanced confidence on sustaining ROA/ROE post Q4.Operating leverage delta will be prominent from Q4 onwards. Amidst intense price wars, preference is to manage ROA threshold over chasing growth.
Not actively resorting to bulk deposits reflects its focus/confidence in mobilizing granular retail deposits.
Citigroup expects a 4% QoQ deposits growth translating to 17-18% YoY growth.
JPMorgan on Bajaj Finance: Overweight| Target Rs 8500
JPMorgan maintained an overweight rating on Bajaj Finance with a target price of Rs 8500. The $9.5 billion valuation of the housing finance subsidiary implies 26x FY26 PE.The listing could place a hold-co discount of 15% on Bajaj Finance. It would potentially remove a medium-term overhang of a bank conversion by 4900 creating two listed NBFCs.
CLSA on Avenue Supermarts: Buy| Target Rs 5307
CLSA maintained a buy rating on Avenue Supermarts but raised the target price to Rs 5307 from Rs 5107 earlier.D-MART opened 16 stores in Q4, three ahead of the forecast. Store additions a key focus point for investors.
Rising inflation in palm oil and crude should allow DMART some room on pricing in FY25.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Source: Stocks-Markets-Economic Times
